Bonum Therapeutics
PrivateLast Round
Early Stage
VC
Apr 3, 2026
Total Funding Raised
$93M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Bonum Therapeutics operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series A round in November 2022.
Bonum Therapeutics is a biopharmaceutical company that develops conditionally active protein-based drugs designed to sense their local environment and activate in response to provide targeted treatments for cancer and other immune-related disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bonum Therapeutics Comparables
Compare Bonum Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Soteria Biotherapeutics | 91% | |
| Tentarix Biotherapeutics | 89% | |
| Trutino Biosciences | 88% |
For institutional investors. Book with your work email.
Bonum Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Apr 3, 2026 | ||||
| Series A | Nov 15, 2022 | ||||
| Early Funding | Dec 8, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bonum Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A |
| Codon Capital | Series A |
| Digitalis Ventures | Series A |
| RiverVest Venture Partners | Series A |
| Roche Venture Fund | Series A |
| 3x5 Partners | Series A |
| Vivo Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 54% MoM.
- Apr 3, 2026
Raised $27M in an early stage VC round.
For institutional investors. Book with your work email.
Bonum Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bonum Therapeutics's valuation, stock price, and market status.
Is Bonum Therapeutics a public or private company?
Bonum Therapeutics is a private company.
What is the current stock price of Bonum Therapeutics?
Bonum Therapeutics is a private company, so its shares have no public market price. Caplight tracks Bonum Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bonum Therapeutics worth (valuation)?
Valuation information for Bonum Therapeutics is not publicly available.
Can I buy Bonum Therapeutics stock?
Bonum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bonum Therapeutics's last funding round?
Bonum Therapeutics's most recent funding round was Early Stage VC on April 3, 2026.
Who are the main investors in Bonum Therapeutics?
Key investors in Bonum Therapeutics include Vivo Capital.
Will Bonum Therapeutics IPO soon?
No public IPO plans have been announced for Bonum Therapeutics.
How can I track Bonum Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Bonum Therapeutics's shares on secondary markets.